This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
The lancet. Diabetes & endocrinology, 13(10), 838-847
Citation
Lim, Soo; Buranapin, Supawan; Bao, Xiaolei; Quiroga, María; Park, Kyung Hee; Kang, Jee-Hyun; Rinnov, Anders Rasmussen; Suwanagool, Arisara. (2025). Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.. The lancet. Diabetes & endocrinology, 13(10), 838-847. https://doi.org/10.1016/S2213-8587(25)00164-0